Revisiting the Role of Acetylcholinesterase in Alzheimer's Disease: Cross-Talk with P-tau and β-Amyloid

Overview

Journal Front Mol Neurosci

Specialty Molecular Biology

Date 2011 Sep 28

PMID 21949503

Citations 92

Authors

Maria-Salud Garcia-Ayllon

David H Small

Jesus Avila

Javier Saez-Valero

Affiliations

Soon will be listed here.

Abstract

A common feature in the Alzheimer's disease (AD) brain is the presence of acetylcholinesterase (AChE) which is commonly associated with β-amyloid plaques and neurofibrillary tangles (NFT). Although our understanding of the relationship between AChE and the pathological features of AD is incomplete, increasing evidence suggests that both β-amyloid protein (Aβ) and abnormally hyperphosphorylated tau (P-tau) can influence AChE expression. We also review recent findings which suggest the possible role of AChE in the development of a vicious cycle of Aβ and P-tau dysregulation and discuss the limited and temporary effect of therapeutic intervention with AChE inhibitors.

Citing Articles

Ferulago angulata Extract Protects against Beta-amyloid-induced Memory Impairment Through Modulation of Monoaminoxidase Enzymes in the Rat's Hippocampus.

Mashhadi-Sharif N, Soodi M, Mirnajafi-Zadeh J, Shadboorestan A, Ebadi-Ramsheh H, Bakhtiarzadeh F Neurochem Res. 2025; 50(2):114.

PMID: 40042687 DOI: 10.1007/s11064-025-04365-3.

Cholinergic neurotransmission in the brain of streptozotocin-induced rat model of sporadic Alzheimer's disease: long-term follow up.

Knezovic A, Salkovic-Petrisic M J Neural Transm (Vienna). 2025; .

PMID: 39891708 DOI: 10.1007/s00702-025-02887-2.

Structure-based virtual screening of Trachyspermum ammi metabolites targeting acetylcholinesterase for Alzheimer's disease treatment.

Musa M, Islam M, Billah W, Hossain M, Rahat M, Bayil I PLoS One. 2024; 19(12):e0311401.

PMID: 39689077 PMC: 11651584. DOI: 10.1371/journal.pone.0311401.

Network Pharmacology, Molecular Dynamics and In Vitro Assessments of Indigenous Herbal Formulations for Alzheimer's Therapy.

Ojo O, Ajayi-Odoko O, Gyebi G, Ayokunle D, Ogunlakin A, Ezenabor E Life (Basel). 2024; 14(10).

PMID: 39459522 PMC: 11508826. DOI: 10.3390/life14101222.

Metformin Mitigates Trimethyltin-Induced Cognition Impairment and Hippocampal Neurodegeneration.

Taheri M, Roghani M, Sedaghat R Cell Mol Neurobiol. 2024; 44(1):70.

PMID: 39441380 PMC: 11499442. DOI: 10.1007/s10571-024-01502-4.

References

Moreno R, Campos F, Dajas F, Inestrosa N . Developmental regulation of mouse brain monomeric acetylcholinesterase. Int J Dev Neurosci. 1998; 16(2):123-34. DOI: 10.1016/s0736-5748(98)00008-2. View

Saez-Valero J, de Ceballos M, Small D, de Felipe C . Changes in molecular isoform distribution of acetylcholinesterase in rat cortex and cerebrospinal fluid after intracerebroventricular administration of amyloid beta-peptide. Neurosci Lett. 2002; 325(3):199-202. DOI: 10.1016/s0304-3940(02)00282-3. View

Basun H, Nilsberth C, Eckman C, Lannfelt L, Younkin S . Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine. Dement Geriatr Cogn Disord. 2002; 14(3):156-60. DOI: 10.1159/000063605. View

Stieger S, Brodbeck U, Witzemann V . Inactive monomeric acetylcholinesterase in the low-salt-soluble extract of the electric organ from Torpedo marmorata. J Neurochem. 1987; 49(2):460-7. DOI: 10.1111/j.1471-4159.1987.tb02887.x. View

Silveyra M, Garcia-Ayllon M, Serra-Basante C, Mazzoni V, Garcia-Gutierrez M, Manzanares J . Changes in acetylcholinesterase expression are associated with altered presenilin-1 levels. Neurobiol Aging. 2011; 33(3):627.e27-37. DOI: 10.1016/j.neurobiolaging.2011.04.006. View

Mesulam M, Geula C . Shifting patterns of cortical cholinesterases in Alzheimer's disease: implications for treatment, diagnosis, and pathogenesis. Adv Neurol. 1990; 51:235-40. View

Chatel J, Grassi J, Frobert Y, Massoulie J, Vallette F . Existence of an inactive pool of acetylcholinesterase in chicken brain. Proc Natl Acad Sci U S A. 1993; 90(6):2476-80. PMC: 46110. DOI: 10.1073/pnas.90.6.2476. View

Dori A, Cohen J, Silverman W, Pollack Y, Soreq H . Functional manipulations of acetylcholinesterase splice variants highlight alternative splicing contributions to murine neocortical development. Cereb Cortex. 2005; 15(4):419-30. DOI: 10.1093/cercor/bhh145. View

Atack J, Perry E, Bonham J, Candy J, Perry R . Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem. 1986; 47(1):263-77. DOI: 10.1111/j.1471-4159.1986.tb02858.x. View

10.

Silveyra M, Cuadrado-Corrales N, Marcos A, Barquero M, Rabano A, Calero M . Altered glycosylation of acetylcholinesterase in Creutzfeldt-Jakob disease. J Neurochem. 2005; 96(1):97-104. DOI: 10.1111/j.1471-4159.2005.03514.x. View

11.

Lahiri D, Farlow M, Nurnberger Jr J, Greig N . Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures. Ann N Y Acad Sci. 1997; 826:416-21. DOI: 10.1111/j.1749-6632.1997.tb48495.x. View

12.

Rossner S, Ueberham U, Schliebs R, Perez-Polo J, Bigl V . The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog Neurobiol. 1998; 56(5):541-69. DOI: 10.1016/s0301-0082(98)00044-6. View

13.

Berson A, Knobloch M, Hanan M, Diamant S, Sharoni M, Schuppli D . Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology. Brain. 2007; 131(Pt 1):109-19. DOI: 10.1093/brain/awm276. View

14.

Brimijoin S, Koenigsberger C . Cholinesterases in neural development: new findings and toxicologic implications. Environ Health Perspect. 1999; 107 Suppl 1:59-64. PMC: 1566370. DOI: 10.1289/ehp.99107s159. View

15.

Darreh-Shori T, Meurling L, Pettersson T, Hugosson K, Hellstrom-Lindahl E, Andreasen N . Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. J Neural Transm (Vienna). 2006; 113(11):1791-801. DOI: 10.1007/s00702-006-0526-2. View

16.

Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt H, Bussche H . Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ. 2005; 331(7512):321-7. PMC: 1183129. DOI: 10.1136/bmj.331.7512.321. View

17.

Zimmermann M, Gardoni F, Marcello E, Colciaghi F, Borroni B, Padovani A . Acetylcholinesterase inhibitors increase ADAM10 activity by promoting its trafficking in neuroblastoma cell lines. J Neurochem. 2004; 90(6):1489-99. DOI: 10.1111/j.1471-4159.2004.02680.x. View

18.

Rieger F, Vigny M . Solubilization and physicochemical characterization of rat brain acetylcholinesterase: development and maturation of its molecular forms. J Neurochem. 1976; 27(1):121-9. DOI: 10.1111/j.1471-4159.1976.tb01553.x. View

19.

Wright C, Geula C, Mesulam M . Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability. Ann Neurol. 1993; 34(3):373-84. DOI: 10.1002/ana.410340312. View

20.

Zimmermann M, Borroni B, Cattabeni F, Padovani A, Di Luca M . Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol Dis. 2005; 19(1-2):237-42. DOI: 10.1016/j.nbd.2005.01.002. View